ovarian cancer Articles
-
Prediction of chemotherapeutic response in ovarian cancer with DNA microarray expression profiling
Abstract Ovarian carcinoma is a leading cause of gynecologic cancer death in women. Despite treatment, a large number of women with ovarian cancer eventually relapse and die of the disease. Hence, recurrent ovarian cancer continues to be a therapeutic dilemma, possibly a result of the emergence of drug resistance during relapse. Recent advances in expression genomics enable global transcript ...
-
Infiltrating Ductal Carcinoma (IDC) - Case Study
Patient with positive family history of breast cancer and ovarian cancer. September 2003 mammogram reported benign micro calcifications. August 2007 patient presented with a palpable mass in lateral aspect of left ...
-
5 year trial involving ovarian cancer patients has found “overall survival benefits” when undergoing surgery using PlasmaJet
A trial involving ovarian cancer patients at Guildford’s Royal Surrey Hospital (UK) has found they have a higher chance of having all the tumour removed when undergoing surgery using argon plasma. Patients who participated in the ‘PlasmaJet® in Ovarian Cancer Surgery’ feasibility study were given a preview of the results as part of Ovarian Cancer Awareness Month recently. ...
-
Early efficacy signals in ovarian cancer patients in ongoing Ph1 trial: Poster reporting findings presented at SITC 2020 Annual Meeting
ENB Therapeutics reports preliminary data from the ongoing Phase 1/2 trial assessing the safety and efficacy of lead product ENB-003 in combination with pembrolizumab. Safety data are encouraging with no significant drug related safety events from the first 3 dosing cohorts. Best overall responses from the first 6 patients include 2 disease stabilizations and 1 confirmed partial response. The ...
-
A Novel Potential Target for CAR-T Cell Therapy in Human Solid Tumors Discovered
At present, chimeric antigen receptor T cell therapy (CAR-T) has made significant achievements in the treatment of specific hematological cancers, allowing patients with relapsed/refractory disease to survive longer and become healthier, but in clinical studies, cell therapy has actually not been successful in the treatment of patients with solid tumors, in part due to the lack of tumor targets ...
-
Cancer Target: Mesothelin
Mesothelin is a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein. Its biological function has not yet been clarified, but due to its limited distribution in normal tissues and high expression in some tumor tissues, it is expected to be used in tumor-specific treatment. In existing studies of human epidermoid carcinoma cell lines expressing mesothelin, biodistribution analysis ...
-
Mesothelin: A New Target for Cancer Therapy
Structure and function of mesothelin The MSLN gene is located in chromosome 16p13. It contains 17 exons, with a cDNA length of about 2138bp, has a 1884-bp open reading frame, and encodes the precursor protein of 628 amino acids (69 kDa). This precursor protein can be hydrolyzed by furin protease into two parts: mesothelin in the size of 40 kDa fragments and 31 kDa secreted fragments called ...
By BOC Sciences
-
Mechanism of Action of Paclitaxel
Paclitaxel is a natural anticancer drug with the molecular formula C47H51NO14. It has been widely used in the clinical treatment of breast cancer, ovarian cancer, and certain head and neck cancers, as well as lung cancer. Its novel and complex chemical structure, extensive and significant biological activity, unique mechanism of action, and scarce natural resources have gained immense favor among ...
By BOC Sciences
-
INOVIQ study validates the use of SubB2M as an aid in diagnosing malignant melanoma
Data from 144 tissue samples in the feasibility study demonstrated that SubB2M immunohistochemistry detected melanoma with 91% sensitivity and discriminated between malignant melanoma and benign skin lesions. SubB2M-based immunohistochemistry applications represent a new product opportunity for SubB2M in the $1.9b immunohistochemistry market. INOVIQ Ltd (ASX:IIQ) has successfully completed ...
By INOVIQ Ltd
-
Abstract A106: Development of IDX-1197, a novel, selective, and highly potent PARP inhibitor
Abstract Background: PARP inhibitors have demonstrated clinically meaningful increase in progression-free survival as a single agent in women with recurrent ovarian cancer following a response to platinum-based chemotherapy. However, there still needs more improvement in efficacy because PARP inhibitors have comparatively low efficacy in non-germline BRCA-mutated patients. We aimed to develop ...
-
Adaptive MRD Chief Commercial Officer Nitin Sood Shares How His Personal Journey Has Shaped His Career Path
Here at Adaptive, putting the patient first is a core value—a philosophy that deeply resonates with me. Similar to many of my fellow Adapters, my inspiration is personal and I’m excited by the tremendous potential impact we can have on human lives through the work we’re doing in our Immune Medicine and MRD businesses. Growing up in New Delhi, India, my father worked for a ...
-
Detailed Introduction to Clinical Significance of Amylase
As a kind of enzymes for diagnostic use. Serum amylase (AMS) is the main type of amylase in serum. It belongs to glycoside chain hydrolase, which is mainly derived from the pancreas. In addition, there are also a small amount of secretion in the proximal duodenum, lung, uterus, and breast during lactation. Amylase plays an important role in the digestion of polysaccharide compounds in food. The ...
-
CADM: A New Generation of Tumor Suppressor Genes
About Tumor Suppressor Genes A tumor suppressor gene, also known as anti-onco gene, is an essential component of the body's defense against cancer. It usually facilitates apoptosis. With its absence, the human body will be functioning without its “brake” of cell proliferation. Cells are potent to go under abnormal growth processes and finally lead to tumor/cancer. Here are some key ...
-
Idience: developing selective and potent PARP inhibitor IDX-1197 for solid tumors
The first wave of PARP inhibitors has improved outcomes in people with a variety of solid tumors. However, Idience has identified opportunities to improve the efficacy of existing drugs and overcome resistance. The company plans to target homologous recombination repair-proficient patients with a clinical-phase PARP inhibitor that is now available for licensing. Ildong Holdings, a major ...
-
Alkaloids: Nature's Chemical Wonders
In the realm of organic chemistry, one class of compounds has captured the scientific community's attention for decades - alkaloids. These naturally occurring compounds are known for their diverse chemical structures and profound biological activities. Many alkaloids have been discovered and studied extensively over the years, with more than 20,000 known alkaloids identified to date. Alkaloids ...
-
An Emerging Aim: ADC Target Protein - Nectin-4
The biologics license application (BLA) has been accepted for Enfortumab Vedotin for the treatment of locally advanced or metastatic urothelial carcinoma in patients who have previously received PD-1/PD-L1 inhibitors and platinum-containing chemotherapy. Enfortumab Vedotin is the first domestically submitted targeted antibody-drug conjugate that specifically targets Nectin-4. Enfortumab ...
-
Abstract 4842: A comparative preclinical study of PARP inhibitors demonstrates superb properties for IDX-1197
Abstract Background PARP inhibitors have demonstrated clinically meaningful increase in progression-free survival as a single agent in women with recurrent ovarian cancer following a response to platinum-based chemotherapy. We aimed to develop a novel PARP inhibitor that may have potent antitumor efficacy. IDX-1197 is a novel, potent, selective, and orally bioavailable poly (ADP-ribose) ...
-
New Study Findings about Glycoprotein PTGDS
Glycoprotein prostaglandin D2 synthase (PTGDS) is a member of the lipocalcitonin superfamily that plays a dual role in prostaglandin metabolism and lipid transport. PTGDS is involved in various cellular processes including solid tumorigenesis, but its role in tumorigenesis is paradoxical, and the significance of PTGDS in hematologic malignancies is not clear. The aim of this new study was to ...
By CD BioGlyco.
-
Introduction and Detection Methods for Phytochemicals
What Are Phytochemicals? Phytochemicals are natural compounds that have only been discovered so far and are natural food pigments. The human body is unable to produce them and must obtain them from food. Soy isoflavones in soybeans, lycopene in tomatoes, catechins in green tea, carotenoids in carrots, zeaxanthin, polyphenols, etc., are all phytochemicals. Classification and Functions of Common ...
-
Modified bacteria produce tetanus toxin, which is utilized to treat fatal pancreatic cancer
Pancreatic cancer is a highly malignant tumor of the digestive tract that is difficult to diagnose and treat, and the morbidity and mortality rates have risen dramatically in recent years. Pancreatic cancer is at an advanced stage when diagnosed when cancer cells have spread and are hard to control. The most frequent pancreatic cancer is pancreatic ductal adenocarcinoma (PDAC), accounting for ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you